CN Patent

CN110585429B — 酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物治疗肿瘤疾病的用途

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2022-10-21 · 4y expired

What this patent protects

本发明涉及酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物治疗肿瘤疾病的用途。具体而言，本发明涉及酪氨酸激酶抑制剂式(I)所示化合物或其复合物或其可药用盐或其立体异构体联合单克隆抗体以及紫杉醇类药物在制备预防或治疗肿瘤疾病的药物中的用途。

USPTO Abstract

本发明涉及酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物治疗肿瘤疾病的用途。具体而言，本发明涉及酪氨酸激酶抑制剂式(I)所示化合物或其复合物或其可药用盐或其立体异构体联合单克隆抗体以及紫杉醇类药物在制备预防或治疗肿瘤疾病的药物中的用途。

Drugs covered by this patent

elacestrant-hydrochloride (ELACESTRANT HYDROCHLORIDE)

Patent Metadata

Patent number: CN110585429B
Jurisdiction: CN
Classification: —
Expires: 2022-10-21
Drug substance claim: No
Drug product claim: No
Assignee: Jiangsu Hengrui Medicine Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.